Wealth Alliance Sells 183 Shares of Charles River Laboratories International, Inc. (NYSE:CRL)

Wealth Alliance lowered its stake in shares of Charles River Laboratories International, Inc. (NYSE:CRL) by 9.6% during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 1,722 shares of the medical research company’s stock after selling 183 shares during the quarter. Wealth Alliance’s holdings in Charles River Laboratories International were worth $318,000 as of its most recent SEC filing.

Other hedge funds have also recently added to or reduced their stakes in the company. Versant Capital Management Inc grew its holdings in Charles River Laboratories International by 1,071.4% during the 4th quarter. Versant Capital Management Inc now owns 164 shares of the medical research company’s stock worth $30,000 after acquiring an additional 150 shares during the last quarter. Pinnacle Bancorp Inc. lifted its position in Charles River Laboratories International by 52.0% during the 4th quarter. Pinnacle Bancorp Inc. now owns 190 shares of the medical research company’s stock valued at $35,000 after purchasing an additional 65 shares during the period. Assetmark Inc. lifted its position in Charles River Laboratories International by 1,153.3% during the 3rd quarter. Assetmark Inc. now owns 188 shares of the medical research company’s stock valued at $37,000 after purchasing an additional 173 shares during the period. ORG Wealth Partners LLC acquired a new position in Charles River Laboratories International during the 4th quarter valued at about $56,000. Finally, Wilmington Savings Fund Society FSB acquired a new position in Charles River Laboratories International during the 3rd quarter valued at about $59,000. Institutional investors own 98.91% of the company’s stock.

Insider Buying and Selling

In other news, EVP Joseph W. Laplume sold 4,400 shares of the firm’s stock in a transaction that occurred on Thursday, February 20th. The shares were sold at an average price of $162.50, for a total transaction of $715,000.00. Following the completion of the transaction, the executive vice president now directly owns 20,013 shares of the company’s stock, valued at $3,252,112.50. This trade represents a 18.02 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, COO Birgit Girshick purchased 1,514 shares of the firm’s stock in a transaction dated Thursday, February 20th. The shares were acquired at an average cost of $164.63 per share, with a total value of $249,249.82. Following the completion of the purchase, the chief operating officer now directly owns 55,058 shares in the company, valued at approximately $9,064,198.54. This represents a 2.83 % increase in their ownership of the stock. The disclosure for this purchase can be found here. 1.30% of the stock is owned by company insiders.

Charles River Laboratories International Price Performance

NYSE CRL opened at $163.11 on Friday. The business has a 50 day simple moving average of $172.84 and a 200 day simple moving average of $188.37. Charles River Laboratories International, Inc. has a 52-week low of $150.79 and a 52-week high of $275.00. The company has a debt-to-equity ratio of 0.65, a quick ratio of 1.14 and a current ratio of 1.41. The stock has a market cap of $8.34 billion, a price-to-earnings ratio of 1,087.39, a PEG ratio of 6.77 and a beta of 1.37.

Charles River Laboratories International (NYSE:CRL) last posted its earnings results on Wednesday, February 19th. The medical research company reported $2.66 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.50 by $0.16. Charles River Laboratories International had a return on equity of 14.69% and a net margin of 0.52%. The business had revenue of $1 billion during the quarter, compared to analysts’ expectations of $983.63 million. During the same period in the prior year, the business earned $2.46 EPS. Charles River Laboratories International’s revenue for the quarter was down 1.1% compared to the same quarter last year. Analysts anticipate that Charles River Laboratories International, Inc. will post 9.41 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of research analysts have issued reports on the stock. Morgan Stanley cut their target price on shares of Charles River Laboratories International from $220.00 to $184.00 and set an “equal weight” rating on the stock in a research report on Wednesday, February 5th. Evercore ISI upped their target price on shares of Charles River Laboratories International from $190.00 to $225.00 and gave the company an “in-line” rating in a research report on Thursday, November 7th. William Blair downgraded shares of Charles River Laboratories International from an “outperform” rating to a “market perform” rating in a research report on Wednesday, January 22nd. Bank of America cut their target price on shares of Charles River Laboratories International from $220.00 to $210.00 and set a “neutral” rating on the stock in a research report on Friday, December 13th. Finally, CLSA downgraded shares of Charles River Laboratories International from a “hold” rating to an “underperform” rating and set a $164.00 target price on the stock. in a research report on Monday, November 18th. Three analysts have rated the stock with a sell rating, thirteen have assigned a hold rating and one has given a buy rating to the company’s stock. According to data from MarketBeat, the company presently has an average rating of “Hold” and a consensus price target of $195.71.

Charles River Laboratories International Company Profile

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).